Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fausto Castagnetti

Showing results (11-20 of 158) with videos related to

Pageof 16
Sort By:
Mediterranean Journal of Hematology and Infectious Diseases|January 24, 2014
Treatment recommendations for chronic myeloid leukemiaMichele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Oncotargets and Therapy|December 3, 2010
Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population characteristicsKimbach Tran Carpiuc, Gianantonio Rosti, Fausto Castagnetti, et al.
Haematologica|November 21, 2007
Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phaseFrancesca Palandri, Ilaria Iacobucci, Fabrizio Quarantelli, et al.
Leukemia & Lymphoma|March 23, 2010
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'Gianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, et al.
Expert Review of Hematology|October 3, 2013
Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitorsGabriele Gugliotta, Fausto Castagnetti, Miriam Fogli, et al.
Haematologica|January 19, 2010
Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patientsFrancesca Palandri, Nicola Polverelli, Emanuela Ottaviani, et al.
Cell Cycle (Georgetown, Tex.)|April 12, 2011
Explaining the in vitro and in vivo differences in leukemia therapyTom Lenaerts, Fausto Castagnetti, Arne Traulsen, et al.
Leukemia Research|April 15, 2011
F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinibAnthony A Oyekunle, Fausto Castagnetti, Gabriele Gugliotta, et al.
Journal of Cellular Biochemistry|November 13, 2014
DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemiaElisa Leo, Manuela Mancini, Fausto Castagnetti, et al.
Leukemia|January 25, 2019
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overviewMichele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Pageof 16

Showing results (11-20 of 158) with videos related to

Sort By:
Pageof 16
Mediterranean Journal of Hematology and Infectious Diseases|January 24, 2014
Treatment recommendations for chronic myeloid leukemiaMichele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Oncotargets and Therapy|December 3, 2010
Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population characteristicsKimbach Tran Carpiuc, Gianantonio Rosti, Fausto Castagnetti, et al.
Haematologica|November 21, 2007
Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phaseFrancesca Palandri, Ilaria Iacobucci, Fabrizio Quarantelli, et al.
Leukemia & Lymphoma|March 23, 2010
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'Gianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, et al.
Expert Review of Hematology|October 3, 2013
Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitorsGabriele Gugliotta, Fausto Castagnetti, Miriam Fogli, et al.
Haematologica|January 19, 2010
Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patientsFrancesca Palandri, Nicola Polverelli, Emanuela Ottaviani, et al.
Cell Cycle (Georgetown, Tex.)|April 12, 2011
Explaining the in vitro and in vivo differences in leukemia therapyTom Lenaerts, Fausto Castagnetti, Arne Traulsen, et al.
Leukemia Research|April 15, 2011
F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinibAnthony A Oyekunle, Fausto Castagnetti, Gabriele Gugliotta, et al.
Journal of Cellular Biochemistry|November 13, 2014
DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemiaElisa Leo, Manuela Mancini, Fausto Castagnetti, et al.
Leukemia|January 25, 2019
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overviewMichele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Pageof 16